{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=58", "query": { "condition": "Ovarian Tumors", "page": 58 }, "page_size": 10 }, "pagination": { "page": 58, "page_size": 10, "total_count": 2464, "total_pages": 247, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=59&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=57&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T05:16:28.120Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02751918", "title": "Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "Anetumab ravtansine (BAY94-9343)", "type": "DRUG" }, { "name": "Pegylated Liposomal Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 65, "start_date": "2016-06-08", "completion_date": "2019-10-31", "has_results": false, "last_update_posted_date": "2019-11-22", "last_synced_at": "2026-10-23T05:16:28.120Z", "location_count": 3, "location_summary": "Aurora, Colorado • New Haven, Connecticut • Oklahoma City, Oklahoma", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT02751918" }, { "nct_id": "NCT03206047", "title": "Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401", "type": "BIOLOGICAL" }, { "name": "Guadecitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Poly ICLC", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 9, "start_date": "2017-11-08", "completion_date": "2020-11-10", "has_results": true, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-23T05:16:28.120Z", "location_count": 17, "location_summary": "Tucson, Arizona • Duarte, California • Sacramento, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03206047" }, { "nct_id": "NCT01248949", "title": "A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Advanced Recurrent Ovarian Tumors" ], "interventions": [ { "name": "MEDI3617", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 162, "start_date": "2010-10", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-03-29", "last_synced_at": "2026-10-23T05:16:28.120Z", "location_count": 10, "location_summary": "Los Angeles, California • Stanford, California • Lafayette, Indiana + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01248949" }, { "nct_id": "NCT06534424", "title": "Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Counseling", "type": "OTHER" }, { "name": "Discussion", "type": "PROCEDURE" }, { "name": "Genotyping", "type": "PROCEDURE" }, { "name": "Molecular Risk Assessment", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 152, "start_date": "2018-01-01", "completion_date": "2023-09-30", "has_results": false, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-10-23T05:16:28.120Z", "location_count": 2, "location_summary": "Columbus, Ohio • Salt Lake City, Utah", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06534424" }, { "nct_id": "NCT04590326", "title": "A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "REGN5668", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Ubamatamab", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 612, "start_date": "2020-12-08", "completion_date": "2028-11-08", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-23T05:16:28.120Z", "location_count": 13, "location_summary": "Duarte, California • Irvine, California • Orange, California + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04590326" }, { "nct_id": "NCT03832985", "title": "Pediatric Reporting of Adult-Onset Genomic Results", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hereditary Breast and Ovarian Cancer Syndrome", "Lynch Syndrome", "Familial Hypercholesterolemia" ], "interventions": [ { "name": "Child(ren) receive an adult-onset result", "type": "GENETIC" }, { "name": "Child(ren) received a pediatric-onset result", "type": "GENETIC" }, { "name": "Control - Negative Result", "type": "GENETIC" }, { "name": "Adolescents who received adult-onset result", "type": "GENETIC" }, { "name": "Adolescents who received a pediatric-onset result", "type": "GENETIC" }, { "name": "Adolescent controls - negative for familial variant", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Geisinger Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 162, "start_date": "2020-11-25", "completion_date": "2024-10-31", "has_results": true, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-10-23T05:16:28.120Z", "location_count": 1, "location_summary": "Danville, Pennsylvania", "locations": [ { "city": "Danville", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03832985" }, { "nct_id": "NCT05032040", "title": "A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Clear Cell Carcinoma", "Endometrial Cancer", "Cervical Carcinoma", "Metastatic Castration-Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "vudalimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2022-07-21", "completion_date": "2025-12-30", "has_results": false, "last_update_posted_date": "2025-02-07", "last_synced_at": "2026-10-23T05:16:28.120Z", "location_count": 17, "location_summary": "Prescott, Arizona • La Jolla, California • Los Angeles, California + 12 more", "locations": [ { "city": "Prescott", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05032040" }, { "nct_id": "NCT04234113", "title": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Thyroid Cancer", "Renal Cell Carcinoma", "Non Small Cell Lung Cancer", "Small-cell Lung Cancer", "Bladder Cancer", "Melanoma", "Merkel Cell Carcinoma", "Skin Squamous Cell Carcinoma", "Microsatellite Instability High", "Triple Negative Breast Cancer", "Mesothelioma", "Thymic Cancer", "Cervical Cancer", "Biliary Tract Cancer", "Hepatocellular Carcinoma", "Ovarian Cancer", "Gastric Cancer", "Head and Neck Squamous Cell Carcinoma", "Anal Cancer" ], "interventions": [ { "name": "Nanrilkefusp alfa", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SOTIO Biotech AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2019-06-13", "completion_date": "2024-11-27", "has_results": true, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-10-23T05:16:28.120Z", "location_count": 3, "location_summary": "New Haven, Connecticut • Pittsburgh, Pennsylvania • Houston, Texas", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04234113" }, { "nct_id": "NCT00088413", "title": "PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenocarcinoma", "Colorectal Cancer", "Ovarian Cancer", "Breast Cancer" ], "interventions": [ { "name": "PANVAC-V", "type": "BIOLOGICAL" }, { "name": "PANVAC-F", "type": "BIOLOGICAL" }, { "name": "Sargramostim (GM-CSF, Leukine)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 51, "start_date": "2004-07-21", "completion_date": "2018-05-31", "has_results": true, "last_update_posted_date": "2019-04-16", "last_synced_at": "2026-10-23T05:16:28.120Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00088413" }, { "nct_id": "NCT03902379", "title": "Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Endometrial Carcinoma", "Stage 0 Fallopian Tube Cancer AJCC v7", "Stage I Fallopian Tube Cancer AJCC v6 and v7", "Stage I Ovarian Cancer AJCC v6 and v7", "Stage IA Fallopian Tube Cancer AJCC v6 and v7", "Stage IA Ovarian Cancer AJCC v6 and v7", "Stage IB Fallopian Tube Cancer AJCC v6 and v7", "Stage IB Ovarian Cancer AJCC v6 and v7", "Stage IC Fallopian Tube Cancer AJCC v6 and v7", "Stage IC Ovarian Cancer AJCC v6 and v7", "Stage II Cervical Cancer AJCC v7", "Stage II Fallopian Tube Cancer AJCC v6 and v7", "Stage II Ovarian Cancer AJCC v6 and v7", "Stage II Uterine Corpus Cancer AJCC v7", "Stage IIA Cervical Cancer AJCC v7", "Stage IIA Fallopian Tube Cancer AJCC v6 and v7", "Stage IIA Ovarian Cancer AJCC V6 and v7", "Stage IIA1 Cervical Cancer AJCC v7", "Stage IIA2 Cervical Cancer AJCC v7", "Stage IIB Cervical Cancer AJCC v6 and v7", "Stage IIB Fallopian Tube Cancer AJCC v6 and v7", "Stage IIB Ovarian Cancer AJCC v6 and v7", "Stage IIC Fallopian Tube Cancer AJCC v6 and v7", "Stage IIC Ovarian Cancer AJCC v6 and v7", "Stage III Cervical Cancer AJCC v6 and v7", "Stage III Fallopian Tube Cancer AJCC v7", "Stage III Ovarian Cancer AJCC v6 and v7", "Stage III Primary Peritoneal Cancer AJCC v7", "Stage III Uterine Corpus Cancer AJCC v7", "Stage IIIA Cervical Cancer AJCC v6 and v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIA Uterine Corpus Cancer AJCC v7", "Stage IIIB Cervical Cancer AJCC v6 and v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIB Uterine Corpus Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IIIC Uterine Corpus Cancer AJCC v7", "Stage IIIC1 Uterine Corpus Cancer AJCC v7", "Stage IIIC2 Uterine Corpus Cancer AJCC v7", "Stage IV Cervical Cancer AJCC v6 and v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7", "Stage IV Uterine Corpus Cancer AJCC v7", "Stage IVA Cervical Cancer AJCC v6 and v7", "Stage IVA Uterine Corpus Cancer AJCC v7", "Stage IVB Cervical Cancer AJCC v6 and v7", "Stage IVB Uterine Corpus Cancer AJCC v7", "Uterine Carcinosarcoma", "Uterine Corpus Sarcoma" ], "interventions": [ { "name": "Internet-Based Intervention", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2016-07-27", "completion_date": "2020-05-31", "has_results": false, "last_update_posted_date": "2021-04-19", "last_synced_at": "2026-10-23T05:16:28.120Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03902379" } ] }